FDA Approved: IRESSA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for IRESSA (gefitinib) from AstraZeneca, updating the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

SUPPL AP for IRESSA (GEFITINIB)